NYSE:ZTSPharmaceuticals
Zoetis Lawsuit Puts Companion Animal Disclosures And Valuation Gap In Focus
Securities class action lawsuit filed against Zoetis (NYSE:ZTS) and certain executives alleging misleading statements about product safety and demand in the Companion Animal division.
Claims focus on disclosures around veterinarian adoption, competitive pressures, and demand trends for key Companion Animal products.
The suit alleges that weakening prescriptions, new competition, and slowing demand were not fully communicated before guidance cuts.
Zoetis, trading at $77.69, is facing this...